Patents by Inventor Deepa Bedi

Deepa Bedi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for the identification of epithelial to mesenchymal breast cancer
    Patent number: 11624748
    Abstract: There is disclosed a method for selectively detecting epithelial to mesenchymal transition (EMT) phenotypic cells but not noncancerous/normal epithelial cells and breast fibroblasts in a biological sample or a patient. The compositions comprise novel binding peptides that specifically bind to EMT cancer cells. EMT phenotypic cells can be identified using the specific peptides and quantitatively measured by detection of a complex of the peptide and a detectable marker. Further, nanodevices incorporating specific EMT phage ligand may be used to identify EMT cancer cells in vivo. Also disclosed are the novel binding phage peptides, and compositions and nanodevices containing the phage ligand for carrying out methods of the invention.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: April 11, 2023
    Assignee: TUSKEGEE UNIVERSITY
    Inventors: Deepa Bedi, Kelvin Jones
  • METHODS AND COMPOSITIONS FOR THE IDENTIFICATION OF EPITHELIAL TO MESENCHYMAL BREAST CANCER
    Publication number: 20210263033
    Abstract: There is disclosed a method for selectively detecting epithelial to mesenchymal transition (EMT) phenotypic cells but not noncancerous/normal epithelial cells and breast fibroblasts in a biological sample or a patient. The compositions comprise novel binding peptides that specifically bind to EMT cancer cells. EMT phenotypic cells can be identified using the specific peptides and quantitatively measured by detection of a complex of the peptide and a detectable marker. Further, nanodevices incorporating specific EMT phage ligand may be used to identify EMT cancer cells in vivo. Also disclosed are the novel binding phage peptides, and compositions and nanodevices containing the phage ligand for carrying out methods of the invention.
    Type: Application
    Filed: December 17, 2020
    Publication date: August 26, 2021
    Applicant: Tuskegee University
    Inventors: Deepa Bedi, Kelvin Jones
  • Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid
    Patent number: 9226972
    Abstract: Disclosed are targeted particles comprising or consisting of a plurality of landscape phage fusion proteins complexed with heterologous nucleic acid, the landscape phage fusion proteins displaying a heterologous peptide and the targeted particle binding specifically to a target site. The particles may be utilized in methods for modulating expression of genes in target cells.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: January 5, 2016
    Assignee: Auburn University
    Inventors: Valery A. Petrenko, Deepa Bedi, Olusegun A. Fagbohun, James W. Gillespie
  • Targeted Particles Comprising Landscape Phage Fusion Proteins and Heterologous Nucleic Acid
    Publication number: 20130202679
    Abstract: Disclosed are targeted particles comprising or consisting of a plurality of landscape phage fusion proteins complexed with heterologous nucleic acid, the landscape phage fusion proteins displaying a heterologous peptide and the targeted particle binding specifically to a target site. The particles may be utilized in methods for modulating expression of genes in target cells.
    Type: Application
    Filed: May 5, 2011
    Publication date: August 8, 2013
    Applicant: AUBURN UNIVERSITY
    Inventors: Valery A. Petrenko, Deepa Bedi, Olusegun A. Fagbohun, James W. Gillespie